Similar articles for PMID: 20426707

Year	Number of Results
1970	1
1985	2
1986	2
1987	2
1988	1
1989	5
1990	1
1991	4
1993	2
1994	2
1995	2
1996	3
1997	3
1998	1
1999	4
2000	2
2001	7
2002	9
2003	3
2004	5
2005	7
2006	4
2007	7
2008	12
2009	20
2010	23
2011	31
2012	24
2013	16
2014	29
2015	28
2016	20
2017	14
2018	5
2019	10
2020	3
2021	12
2022	4
2023	2
2024	0

1

Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.

Elborn JS, Henig NR. Elborn JS, et al. Expert Opin Pharmacother. 2010 Jun;11(8):1373-85. doi: 10.1517/14656566.2010.482102. Expert Opin Pharmacother. 2010. PMID: 20426707 Review.

2

Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.

Parkins MD, Elborn JS. Parkins MD, et al. Expert Rev Respir Med. 2010 Aug;4(4):435-44. doi: 10.1586/ers.10.48. Expert Rev Respir Med. 2010. PMID: 20658904 Review.

3

A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.

Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL; AZLI Phase II Study Group. Retsch-Bogart GZ, et al. Pediatr Pulmonol. 2008 Jan;43(1):47-58. doi: 10.1002/ppul.20736. Pediatr Pulmonol. 2008. PMID: 18041081 Clinical Trial.

4

Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.

Pesaturo KA, Horton ER, Belliveau P. Pesaturo KA, et al. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1076-85. doi: 10.1345/aph.1Q653. Epub 2012 Jul 3. Ann Pharmacother. 2012. PMID: 22764322 Review.

5

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.

Wainwright CE, Quittner AL, Geller DE, Nakamura C, Wooldridge JL, Gibson RL, Lewis S, Montgomery AB. Wainwright CE, et al. J Cyst Fibros. 2011 Jul;10(4):234-42. doi: 10.1016/j.jcf.2011.02.007. Epub 2011 Mar 26. J Cyst Fibros. 2011. PMID: 21441078 Free article. Clinical Trial.

6

Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).

Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. Oermann CM, et al. J Antimicrob Chemother. 2011 Oct;66(10):2398-404. doi: 10.1093/jac/dkr303. Epub 2011 Jul 22. J Antimicrob Chemother. 2011. PMID: 21784781 Clinical Trial.

7

Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. McCoy KS, et al. Am J Respir Crit Care Med. 2008 Nov 1;178(9):921-8. doi: 10.1164/rccm.200712-1804OC. Epub 2008 Jul 24. Am J Respir Crit Care Med. 2008. PMID: 18658109 Free PMC article. Clinical Trial.

8

Inhaled aztreonam lysine: an evidence-based review.

Hutchinson D, Barclay M, Prescott WA, Brown J. Hutchinson D, et al. Expert Opin Pharmacother. 2013 Oct;14(15):2115-24. doi: 10.1517/14656566.2013.831070. Epub 2013 Aug 31. Expert Opin Pharmacother. 2013. PMID: 23992352 Review.

9

Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.

Tiddens HA, De Boeck K, Clancy JP, Fayon M, H G M A, Bresnik M, Derchak A, Lewis SA, Oermann CM; ALPINE study investigators. Tiddens HA, et al. J Cyst Fibros. 2015 Jan;14(1):111-9. doi: 10.1016/j.jcf.2014.06.003. Epub 2014 Aug 1. J Cyst Fibros. 2015. PMID: 25091537 Free article. Clinical Trial.

10

Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Assael BM. Assael BM. Expert Rev Anti Infect Ther. 2011 Nov;9(11):967-73. doi: 10.1586/eri.11.131. Expert Rev Anti Infect Ther. 2011. PMID: 22029514 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

294 results

Results by year